Kaitlyn D’Onofrio

DocwireNews

A study published in <a href="https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-020-02199-8">Arthritis Care &amp; Research</a> analyzed the effects of brief treatment interruptions on <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/what-symptoms-do-ra-patients-consider-the-most-important/">rheumatoid arthritis (RA) symptoms</a> among patients taking baricitinib and found that this may result in minor, temporary symptom increases.&ldquo;Temporary interruption of <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/heres-how-rheumatic-patients-were-affected-during-the-early-days-of-the-covid-19-pandemic/">rheumatoid arthritis (RA)</a> therapy is common in clinical practice for various reasons including side effects, non-compliance, or necessity for surgery. Short half-life and low immunogenicity may therefore be useful attributes for disease-modifying antirheumatic drugs (DMARDs). Few studies examine what happens when DMARDs are temporarily interrupted and then restarted despite concerns of symptoms worsening or immunogenicity increasing after the stoppage. If disease activity deteriorates, there is also the question of whether it will improve once the drug is started again,&rdquo; the study authors explained.To assess the effect of temporary baricitinib cessation, they examined patients with moderate-to-severe RA in four phase 3 studies that compared cessation of baricitinib versus placebo-matched tablets, assessing timing, reason, and duration of investigator-initiated temporary study drug interruptions. Two of the studies required patients to record RA symptoms daily for 12 weeks. Changes in symptom scores during interruptions and resumption of treatment were observed in post hoc analyses. When looking at interruptions, investigators assessed reoccurrence of adverse events and laboratory abnormalities after retreatment.In the placebo-controlled studies, interruptions took place in greater proportions of patients treated with baricitinib (2 mg, 18%; 4 mg, 18%) compared to placebo (9%) in only one study (bDMARD-inadequate responder patients, RA-BEACON). In the active comparator-controlled studies, in RA-BEGIN, the lowest rates of interruption were observed in the baricitinib monotherapy arm (9%), compared to <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/triple-therapy-versus-tnfi-plus-methotrexate-for-rheumatoid-arthritis-a-real-world-treatment-comparison/">methotrexate</a> monotherapy or combination therapy, while in RA-BEAM, similar outcomes were observed in patients on baricitinib (10%) and adalimumab (9%). The most commonly cited reason for interruption was adverse events, but reoccurrence was infrequent when the drug was restarted. Interruptions tended to last for two weeks or less. Based on patients&rsquo; daily diaries, modest symptom increases were observed during interruption, but upon resumption, symptoms returned to pre-interruption levels or better. Long-term efficacy outcomes were not affected by interruptions.&ldquo;Consistent with its pharmacologic properties, temporary interruption of baricitinib during phase 3 studies was not followed by significant reactivation of disease and baricitinib was rarely interrupted again after an initial interruption. The present study should serve to provide useful information for clinicians, as temporary interruption of antirheumatic therapy is common in the care of patients with RA,&rdquo; summarized the authors.

Connie Rhee, MD

Joel M. Topf, MD, FACP

CKD Management and Cognition

NKF Spring Clinical Meetings 2025

Bradley Marder, MD

Gout Studies: Transplant Waitlisting and Bone Erosion

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Latest News

Brief Treatment Interruptions May Temporarily Increase RA Symptoms in Patients Taking Baricitinib

Rheumatoid Arthritis

A study published in Arthritis Care &amp; Research analyzed the effects of brief treatment interruptions on rheumatoid arthritis (RA) symptoms among patients taking ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe